Benitec Biopharma Inc. (BNTC) News
Follow Benitec Biopharma Inc. (BNTC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Benitec Reports Positive Interim BB-301 Phase 1b/2a Results
Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements for low-dose BB-301.
EQUITY | Oct 28, 2026, 12:13 PM UTC
L
Benitec Biopharma Price Target Raised to $17.00/Share From $16.00 by Wedbush
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:48 PM UTC
L
Benitec Biopharma Inc. FY 2026: Revenue $0 EPS $(0.98) — 10-K Summary
Benitec Biopharma Inc. reported a net loss of $45.5M for fiscal 2026, compared with a $37.9M loss in fiscal 2025, with no product revenue recognized in either year and diluted EPS of $(0.98) for FY 2026 versus $(1.05) in
EARNINGS | Sep 14, 2026, 08:26 PM UTC
L
Benitec Biopharma reports FY2026 net loss $45.5M, cash $180.0M; advances BB-301 clinical program
Benitec Biopharma reported a net loss of $45.5 million for the year ended June 30, 2026, compared with a $37.9 million loss the prior year, and held $180.0 million in cash and cash equivalents at year-end. Total operatin
EARNINGS | Sep 14, 2026, 08:14 PM UTC
L
BNTC: Net loss widened to $45.5M in FY 2026, with $180M cash on hand and no revenue generated
The company reported a net loss of $45.5 million for FY 2026, with no revenue and increased R&D and G&A expenses. Cash reserves of $180 million are expected to fund operations for at least twelve months, but ongoing loss
EARNINGS | Sep 14, 2026, 08:13 PM UTC
L
BNTC: BB-301 clinical progress and robust cash reserves highlight a year of operational and financial momentum
BB-301 clinical development advanced with full enrollment of Cohort 2 and positive interim results, while a strong cash position of $180 million supports ongoing operations. Net loss widened to $45.5 million as R&D and G
EARNINGS | Sep 14, 2026, 08:06 PM UTC
L
Benitec Biopharma FY26 Loss $45.5M >BNTC
Benitec Biopharma FY26 Loss $45.5M >BNTC
EQUITY | Sep 14, 2026, 08:01 PM UTC
L
BNTC - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
BNTC - Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
EARNINGS | Sep 14, 2026, 08:00 PM UTC
L
BNTC Initiated Outperform W/$16.00 PT at Wedbush
BNTC Initiated Outperform W/$16.00 PT at Wedbush
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC